The Priority Review

Tag

HS-10382

1 story

  1. Clinical trials

    Jiangsu Hansoh registers Phase 3 trial of HS-10382 in newly diagnosed Ph+ CML-CP

    The study, led by Jiangsu Hansoh Pharmaceutical Co., Ltd., plans to enroll 408 participants and has a planned start date of December 2026. It evaluates the efficacy of oral HS-10382 versus investigator-selected TKIs-imatinib, nilotinib, dasatinib, and flumatinib-in adult patients with newly diagnosed Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia.